600 patients66,869 observations120 daysLIVE

Patient P-01559

Synthetic patientNBL-101 · Day 119 · 45–54 · F · baseline S06Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S06
  2. Day 47 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 60 GI-04 recommendedGI Support Protocol GI-04
  4. Day 61 Patient acceptedStarted GI-04 in the companion
  5. Day 67 ME-01 recommendedMonitoring Escalation ME-01
  6. Day 68 Patient acceptedStarted ME-01 in the companion
  7. Day 69 GI symptom burden −29% vs expectedGI Support Protocol GI-04
  8. Day 71 Deterioration detected before clinical escalationMonitoring Escalation ME-01
  9. Day 75 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • Inflammatory activity+10
  • Treatment adherence+5
  • GI instability+4
  • Nutritional resilience+3
  • Toxicity-2

What helped?

  • GI Support Protocol GI-04Day 60
    Result: symptom burden −29%
  • Monitoring Escalation ME-01Day 67
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
55%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
44.4/100
improving · -10.0 vs previous 14 d
Toxicity
Blood
40.3/100
stable · -0.2 vs previous 14 d
Sleep quality
Wearable
33.2/100
improving · +4.3 vs previous 14 d
Energy level
Daily log
3.9/10
improving · +0.3 vs previous 14 d
Stress level
Daily log
5.7/10
improving · -0.3 vs previous 14 d
Steps
Wearable
7,728
improving · +769 vs previous 14 d
Adherence
Companion
50.9 %
improving · +2.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 35 from the failing basin, 52 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 66%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 66%
  • CR-01 Clinician Review
    100% improved among 7 similar · onset 5 d · confidence 66%
Would not help
  • Keep fat low
    GI +4.4 next day on high-intake days · n 17
  • Keep histamine low
    GI +4 next day on high-intake days · n 20
  • Keep alcohol low
    GI +3.7 next day on high-intake days · n 21
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +4.4detractor · 95%
  • Histamine load
    +4detractor · 95%
  • Alcohol
    +3.7detractor · 95%
  • Simple carbohydrates
    +3detractor · 95%
  • Insoluble fibre
    -0.5no signal · 15%
  • Spicy / capsaicin
    +0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 23/100
    • MicrobiomeF. prausnitzii depleted
  • Autonomic recovery 45
    • WearableResting HR 78 bpm
    • WearableShort sleep window
  • Mucosal barrier integrity 30
    • DNAFUT2 non-secretor lowers mucosal fucosylation
  • Inflammatory signalling 25
    • BloodInflammatory load index 49
  • Drug metabolism and exposure 20
    • BloodToxicity index 40
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 23/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
59 ms
Sleep
6.5 h
Steps
8,420
Resting HR
76 bpm
Daily log: GI score 44, nutritional resilience 50, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0132740%S01GI-04improved56
P-0168837%S01GI-04improved40
P-0181333%S01NP-02no change40
P-0131029%S0157
P-0182125%S0158
P-0182324%S0157
P-0184624%S0137
P-0163542%S02GI-04improved49
P-0145237%S02GI-04improved46
P-0145929%S0251
P-0149825%S0256
P-0174124%S0255